Comparative Analyses of Pharmaceuticals or Food Supplements Containing Chondroitin Sulfate: Are Their Bioactivities Equivalent?

Abstract

IntroductionOral supplementation of chondroitin sulfate (CS) and glucosamine (GlcN), symptomatic slow-acting molecules, is recommended by European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis and Musculoskeletal Diseases (ESCEO) and other European Union (EU) guidelines for the restoration of the articular cartilage surface in patients affected by osteoarthritis (OA). They are commercialized as pharmaceutical grade products and as food supplements in combination with plant extracts hyaluronic acid, methylsulfonylmethane, and other components. Food supplements do not need to undergo the strict regulatory controls of pharmaceutical grade products; thus, composition and contaminants that could be present may not be evidenced before commercialization and these uncertainties may give rise to concerns about the bioactivity of these formulations.MethodsIn this paper 10 different food supplements (FS) from diverse European countries were analyzed in comparison with two pharmaceutical grade products (Ph) using updated analytical approaches and biochemical cell-based assays. The purity, the titer, and the origin of CS in Ph and FS samples were initially assessed in order to successively compare the biological function. Both food supplements and pharmaceutical formulations were tested in vitro, using the same final CS concentration, on primary chondrocytes and synoviocytes in terms of (i) cell viability, (ii) activation of the NF-κB-mediated inflammation pathway, (iii) cartilage oligomeric matrix protein (COMP-2), IL-6, and IL-8 production.ResultsAll the FS presented a certain insoluble fraction; the CS and the GlcN contents were lower than the declared ones in 9/10 and 8/10 samples, respectively. All FS contained keratan sulfate (KS) at up to 50% of the total glycosaminoglycan amount declared on the label. Primary cells treated with the samples diluted to present the same CS concentration in the medium showed cytotoxicity in 7/10 FS while Ph preserved viability and reduced NF-κB, COMP-2, and secreted inflammatory cytokines.ConclusionAmong all samples tested, the pharmaceutical grade products demonstrated effective modulation of biomarkers counteracting the inflammation status and improving viability and the physiological condition of OA human primary chondrocyte and synoviocyte cells. In contrast to that, most FS were cytotoxic at the tested concentrations, and only 3/10 of them showed similarities to Ph sample behavior in vitro.FundingThis work was partially supported by PON01_1226 NUTRAFAST, MIUR Ministero dell’Università e della Ricerca Scientifica. Bioteknet financed two short-term grants for graduate technicians. The journal’s Rapid Service and Open Access fees were funded by IBSA CH.

Arctigenin prevents the progression of osteoarthritis by targeting PI3K/Akt/NF‐κB axis: In vitro and in vivo studies

“…Although there are already drugs for OA in the market, such as sodium hyaluronate, NASIDs, glucosamine, chondroitin sulphate, most of them were proved to relive the pain of joint, but whether it could truly prevent the progression of OA is still debatable and many side effects were also reported . Thus, our present study is trying to find a safer agent‐derived natural plant, which could truly attenuate OA with little side effects.…”

Differential Secretome Profiling of Human Osteoarthritic Synoviocytes Treated with Biotechnological Unsulfated and Marine Sulfated Chondroitins

“…Then, following the extensive washing of cells with PBS, medium containing 0.5% FBS was added. After 24 h, cells were further washed five times (10 mL each) with PBS and cultured in serum-free medium with or without CS (3.2 mg/mL) and BC (3.2 mg/mL) for 48 h. CS and BC concentrations used in this study were optimized in accordance with previous investigation [69]. At the end of incubation, media were centrifuged (1500 rpm, 7 min) and supernatants stored at −80 • C.…”

An in vitro study to assess the effect of hyaluronan-based gels on muscle-derived cells: Highlighting a new perspective in regenerative medicine

“…The fact that linear HA with different molecular weights produces different effects is well documented, and currently, many formulations based on linear and/or chemically cross-linked HA are used in dermo-aesthetic, wound healing, and ophthalmic applications [ 16 ]. Additionally, as a result of its natural presence in the synovial fluid, joint capsule, and articular cartilage, HA is widely used in the treatment of osteoarthritis or rheumatoid arthritis [ 17 – 19 ]. In addition to linear HAs, the novel stabilized hybrid cooperative complexes (HCC) derived from high and low molecular weight HA through NAHYCO TM technology has been reported to be used in several in vitro studies based on different cellular models [ 20 ].…”